From Name:
From Email:
To Name:
To Email:

Optional Message:

FDA staff flag concerns about Allergan's urinary drug

from Reuters

The proposed dosing for a drug being developed by Allergan Plc to treat frequent urination at night has not been adequately studied in trials, a preliminary review by the U.S. Food and Drug Administration staff concluded. The drug, SER120, is a low-dose nasal version of the commonly used treatment, desmopressin, and is designed to treat adults with nocturia, a disorder where a person wakes up to urinate twice or more at night. There are no FDA-approved drugs to specifically treat nocturia. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063